Pyridoxine ( DrugBank: Pyridoxine )
3 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 93 | Primary biliary cholangitis | 1 |
| 145 | West syndrome | 1 |
| 320 | Inherited glycosylphosphatidylinositol deficiency | 1 |
93. Primary biliary cholangitis
Clinical trials : 282 / Drugs : 245 - (DrugBank : 56) / Drug target genes : 35 - Drug target pathways : 113
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2006-006742-34-GB (EUCTR) | 20/12/2007 | 03/06/2007 | The effect of Ezetimibe or pyridoxine in Patients with Primary Biliary Cirrhosis. | The effect of Ezetimibe or pyridoxine in Patients with Primary Biliary Cirrhosis. | primary biliary cirrhosis MedDRA version: 9.1;Level: LLT;Classification code 10036680;Term: Primary biliary cirrhosis | Trade Name: Ezetrol Product Name: Ezetimibe Product Code: EZT INN or Proposed INN: EZETIMIBE Trade Name: pyridoxine 10mg BP Product Name: pyridoxine 10mg Product Code: A11HA02 INN or Proposed INN: PYRIDOXINE | Barts and The London NHS Trust | NULL | Not Recruiting | Female: yes Male: yes | 70 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): yes | United Kingdom |
145. West syndrome
Clinical trials : 43 / Drugs : 54 - (DrugBank : 15) / Drug target genes : 27 - Drug target pathways : 24
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01828437 (ClinicalTrials.gov) | November 2012 | 7/4/2013 | Addition of Pyridoxine to Prednisolone in Infantile Spasms | Addition of Pyridoxine to Prednisolone in the Treatment of Infantile Spasms: A Randomized Controlled Trial | Infantile Spasms | Drug: Pyridoxine plus prednisolone;Drug: Prednisolone | Lady Hardinge Medical College | NULL | Completed | 3 Months | 36 Months | All | 62 | Phase 3 | India |
320. Inherited glycosylphosphatidylinositol deficiency
Clinical trials : 3 / Drugs : 2 - (DrugBank : 2) / Drug target gene : 0 - Drug target pathway : 0
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-UMIN000024185 | 2014/07/31 | 27/09/2016 | Prospective non- control non- randomized, open-label study about efficacy of vitamin B6 for inherited GPI deficiency | Prospective non- control non- randomized, open-label study about efficacy of vitamin B6 for inherited GPI deficiency - Interventional study of vitamin B6 for inherited GPI deficiency | Inherited GPI deficiency | Initial dose: pyridoxine 10-15 mg/kg/day 1-2 weeks after the initiation, the dose is increased to maintenance dose, if there is no adverse effect. Maintenance dose: pyridoxine 20-30 mg/kg/day We prescribe pyridoxine for a year. | The Graduate School of Medicine, Osaka University | Department of Child Neurology, Tottori University Hospital | Complete: follow-up complete | Not applicable | Not applicable | Male and Female | 15 | Not selected | Japan |